American Association for Cancer Research (AACR) Annual Meeting
April 8 - April 13, 2022
April 8-13, 2022.
Poster Title: An ‘Anti-PD1-IL2 Beta-Only Super-Agonist’ Displays Potent Anti-Tumor Efficacy
Session Category: Immunology
Session Title: Preclinical Immunotherapy
Location: On-line only
Abstract Number: 5532
This poster will describe preclinical studies evaluating a therapeutic candidate derived from Medicenna’s BiSKITs™ program (Bifunctional SuperKine ImmunoTherapies). The evaluated bifunctional Superkine is designed to activate anti-cancer immune cells while limiting their exhaustion, and is composed of an anti-PD-1 antibody linked to an IL-2 Superkine exhibiting enhanced affinity for IL-2 receptor beta, and no binding to IL-2 receptor alpha.
Poster Title: Characterization of a Long-Acting IL-13 Super-Antagonist Engineered to Target Tumor Associated Macrophages and Myeloid Cells
Session Category: Immunology
Session Title: Preclinical Immunotherapy
Location: On-line only
Abstract Number: 5542
This poster will describe preclinical studies evaluating a long-acting IL-4/IL-13 super-antagonist that targets the IL-13 receptor alpha-1 component of type II IL-4 receptor expressed on tumor associated macrophages and myeloid derived suppressor cells. Inhibition of this receptor with the super-antagonist is intended to prevent tumor growth by promoting a pro-inflammatory tumor microenvironment.